Currax patents expiration
1. Onzetra Xsail patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6715485 | CURRAX | Nasal delivery device |
Mar, 2020
(4 years ago) | |
| US8555877 | CURRAX | Nasal delivery device |
Mar, 2020
(4 years ago) | |
| US8047202 | CURRAX | Nasal devices |
Jul, 2023
(9 months ago) | |
| US8327844 | CURRAX | Nasal delivery method |
Oct, 2023
(6 months ago) | |
| US9119932 | CURRAX | Nasal delivery device |
Apr, 2024
(16 hours ago) | |
| US7975690 | CURRAX | Nasal devices |
Aug, 2025
(1 year, 3 months from now) | |
| US9108015 | CURRAX | Nasal delivery devices |
Sep, 2025
(1 year, 4 months from now) | |
| US8590530 | CURRAX | Nasal delivery devices |
Sep, 2025
(1 year, 4 months from now) | |
| US11571531 | CURRAX | Powder delivery devices |
Feb, 2026
(1 year, 10 months from now) | |
| US10124132 | CURRAX | Nasal delivery |
Mar, 2027
(2 years from now) | |
| US10398859 | CURRAX | Nasal delivery devices |
Dec, 2027
(3 years from now) | |
| US8875704 | CURRAX | Nasal administration |
Apr, 2028
(3 years from now) | |
| US10722667 | CURRAX | Nasal administration |
Dec, 2028
(4 years from now) | |
| US10076615 | CURRAX | Nasal delivery |
Jul, 2029
(5 years from now) | |
| US8550073 | CURRAX | Nasal delivery |
Oct, 2029
(5 years from now) | |
| US8899229 | CURRAX | Powder delivery devices |
Aug, 2030
(6 years from now) | |
| US9649456 | CURRAX | Nasal administration |
Oct, 2030
(6 years from now) | |
| US8978647 | CURRAX | Nasal delivery |
Dec, 2030
(6 years from now) | |
| US10478574 | CURRAX | Nasal administration |
Nov, 2033
(9 years from now) | |
| US10076614 | CURRAX | Nasal delivery devices |
Oct, 2034
(10 years from now) | |
Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 27 January, 2016
Treatment: Method of drug delivery via the nasal cavity; Treatment of migraine via delivery of sumatriptan via the nasal cavity; Method of delivering sumatriptan to a nasal cavity; Acute treatment of migraine by...
Dosage: POWDER;NASAL
ONZETRA XSAIL family patents
2. Silenor patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5502047 | CURRAX | Treatment for insomnia |
Mar, 2013
(11 years ago) | |
| US5585115 | CURRAX | Pharmaceutical excipient having improved compressability |
Jan, 2015
(9 years ago) | |
| US6217909 | CURRAX | Pharmaceutical excipient having improved compressibility |
Jan, 2015
(9 years ago) | |
| US6103219 | CURRAX | Pharmaceutical excipient having improved compressibility |
Jan, 2015
(9 years ago) | |
| US5725884 | CURRAX | Pharmaceutical excipient having improved compressibility |
Jan, 2015
(9 years ago) | |
| US5866166 | CURRAX | Pharmaceutical excipient having improved compressibility |
Jan, 2015
(9 years ago) | |
| US5948438 | CURRAX | Pharmaceutical formulations having improved disintegration and/or absorptivity |
Jan, 2015
(9 years ago) | |
| US6211229 | CURRAX | Treatment of transient and short term insomnia |
Feb, 2020
(4 years ago) | |
| US10653662 | CURRAX | Methods of using low-dose doxepin for the improvement of sleep |
May, 2027
(3 years from now) | |
| US9486437 | CURRAX | Methods of using low-dose doxepin for the improvement of sleep |
May, 2027
(3 years from now) | |
| US9861607 | CURRAX | Methods of using low-dose doxepin for the improvement of sleep |
May, 2027
(3 years from now) | |
| US10238620 | CURRAX | Methods of using low-dose doxepin for the improvement of sleep |
May, 2027
(3 years from now) | |
| US11110074 | CURRAX | Methods of improving the pharmacokinetics of doxepin |
Jul, 2027
(3 years from now) | |
| US10653660 | CURRAX | Methods of improving the pharmacokinetics of doxepin |
Jul, 2027
(3 years from now) | |
| US9572814 | CURRAX | Methods of improving the pharmacokinetics of doxepin |
Jul, 2027
(3 years from now) | |
| US7915307 | CURRAX | Methods of improving the pharmacokinetics of doxepin |
Aug, 2027
(3 years from now) | |
| US11234954 | CURRAX | Low-dose doxepin for treatment of sleep disorders in elderly patients |
Jan, 2028
(3 years from now) | |
| US10548871 | CURRAX | Low-dose doxepin formulations and methods of making and using the same |
Apr, 2028
(3 years from now) | |
| US9907780 | CURRAX | Low-dose doxepin formulations and methods of making and using the same |
Apr, 2028
(3 years from now) | |
| US11096920 | CURRAX | Low-dose doxepin formulations and methods of making and using the same |
Apr, 2028
(3 years from now) | |
| US9107898 | CURRAX | Methods of using low-dose doxepin for the improvement of sleep |
May, 2028
(4 years from now) | |
| US9532971 | CURRAX | Low-dose doxepin formulations and methods of making and using the same |
Jun, 2029
(5 years from now) | |
| US8513299 | CURRAX | Methods of using low-dose doxepin for the improvement of sleep |
Sep, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 17, 2013 |
Drugs and Companies using DOXEPIN HYDROCHLORIDE ingredient
Market Authorisation Date: 17 March, 2010
Treatment: Treatment of insomnia
Dosage: TABLET;ORAL
SILENOR family patents
3. Treximet patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6060499 | CURRAX | Anti-migraine methods and compositions using 5-HT agonists with long-acting NSAIDs |
Aug, 2017
(6 years ago) | |
| US6586458 | CURRAX | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
Aug, 2017
(6 years ago) | |
| US5872145 | CURRAX | Formulation of 5-HT agonist and NSAID for treatment of migraine |
Aug, 2017
(6 years ago) | |
| US8022095 | CURRAX | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
Aug, 2017
(6 years ago) | |
|
US6060499 (Pediatric) | CURRAX | Anti-migraine methods and compositions using 5-HT agonists with long-acting NSAIDs |
Feb, 2018
(6 years ago) | |
|
US8022095 (Pediatric) | CURRAX | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
Feb, 2018
(6 years ago) | |
|
US6586458 (Pediatric) | CURRAX | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
Feb, 2018
(6 years ago) | |
|
US5872145 (Pediatric) | CURRAX | Formulation of 5-HT agonist and NSAID for treatment of migraine |
Feb, 2018
(6 years ago) | |
| US7332183 | CURRAX | Multilayer dosage forms containing NSAIDs and triptans |
Oct, 2025
(1 year, 5 months from now) | |
|
US7332183 (Pediatric) | CURRAX | Multilayer dosage forms containing NSAIDs and triptans |
Apr, 2026
(1 year, 11 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 14, 2018 |
| Pediatric Exclusivity(PED) | Nov 14, 2018 |
Drugs and Companies using NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 14 May, 2015
Treatment: Treatment of migraine; Acute treatment of migraine
Dosage: TABLET;ORAL
TREXIMET family patents